Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases

Shuheng Shang1,2
Yi Su1
Zhaofeng Zhu4
Butuo Li2,5
Meiying Guo1,2
Yiyue Xu1,2
Xindong Sun2
Linlin Wang2
Jinming Yu2

1Department of Radiation Oncology, School of Medicine, Shandong University, Jinan, China; 2Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, China; 3Department of Radiotherapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University Institution, Yantai, China; 4Department of Radiotherapy, Tai’an Central Hospital, Tai’an, China; 5Department of Radiation Oncology, Tianjin Medical University, Tianjin, China

Correspondence: Linlin Wang; Jinming Yu
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, No 440, Jyan Road, Jinan 250117, China
Tel +86 531 6762 6142;
+86 531 8798 4729
Fax +86 531 6762 6141;
+86 531 8798 4729
Email wanglinlinatjn@163.com; sdyujinming@163.com

Background: The optimal treatment strategy for patients with non-small-cell lung cancer (NSCLC) with postoperative oligometastases is poorly defined. This two-institution analysis sought to retrospectively compare the efficacy and toxicity of local ablative treatment plus chemotherapy vs local treatment alone in patients with NSCLC who developed oligometastases after surgery.

Patients and methods: Among patients who underwent surgery for stage I–III NSCLC, 163 patients with oligometastases were enrolled between 2005 and 2016 in this study. All patients had ≤5 metachronous metastases with a disease-free interval (DFI) of ≥6 months after surgery. Patients with a second primary cancer, local recurrence, or driver mutations were excluded. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), failure patterns, and treatment-related toxicities were compared between groups receiving local ablative treatment plus chemotherapy and local treatment alone.

Results: A total of 105 patients who underwent local ablative therapy combined with chemotherapy and 58 patients who received local ablative therapy alone were included in this study. The median follow-up was 19 (range, 1.5–107) months. The combination therapy group had a higher ORR than the local therapy alone group (66.7% vs 46.5%, P=0.012), while the median PFS was 10 vs 7 months (P=0.006) and the median OS was 19 vs 18.5 months (P=0.498), respectively. By multivariate analysis, combination therapy and DFI ≥24 months were associated with superior PFS. Age was the only independent prognostic factor for OS (P=0.001). The incidences of grade ≥3 adverse events were higher in the combination treatment group.

Conclusion: Local ablative therapy plus chemotherapy conferred higher ORR and prolonged PFS but did not improve OS in NSCLC patients with postoperative oligometastases. Further prospective and randomized trials are urgently needed to validate these findings.

Keywords: postoperaton, oligometastases, non-small-cell lung cancer, local ablative therapy, chemotherapy

Introduction

Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide, and its prevalence continues to increase in China, which has the highest morbidity and mortality rates. Surgery is the major treatment strategy for most patients with stage I–III NSCLC; however, unfortunately, 19.3%–68.2%1–5 of these patients develop postoperative recurrences. Systemic chemotherapy or targeted molecular therapy is commonly accepted as standard management practice for patients with recurrent NSCLC, based on the evidence of metastatic stage IV disease. Nevertheless,
outcomes remain poor for patients with recurrent NSCLC, with postrecurrence survival (PRS) of 8.1–20.7 months.\(^6\)

Most postoperative recurrence is distant, with half including oligometastases,\(^7\) an intermediate state between local lesions and systemic metastases.\(^8\) For patients with oligometastatic NSCLC (stage IV, M1b), local ablative therapy combined with chemotherapy can dramatically improve progression-free survival (PFS) without significant toxicities.\(^9\) In patients with postoperative oligometastases, the addition of chemotherapy to stereotactic body radiation therapy (SBRT) is also reported to predict significantly superior local control and confer improved overall survival (OS).\(^10\)

In addition, local radiotherapy combined with systemic treatment conferred a better 2-year survival rate compared with radiotherapy alone,\(^11\) demonstrating that the combination of local and systemic treatments may also be promising for the management of postoperative oligometastases.

Nevertheless, postoperative oligometastases do not behave in the same way as stage IV disease detected at original diagnosis.\(^12\) As primary lesions are completely resected and since oligometastases have less aggressive biological characteristics than polymetastases,\(^13\) local therapy alone has also been attempted for NSCLC patients with postoperative oligometastases. Local therapy alone could successfully control brain,\(^14\) adrenal,\(^15\) and lung\(^16\) oligometastases, leading to long-term survival; moreover, the addition of chemotherapy to local radiotherapy did not improve survival outcomes.\(^17,18\)

Given the lack of evidence from prospective and randomized clinical trials, the optimal treatment paradigms for postoperative oligometastases remain to be determined. Therefore, we retrospectively compared the efficacy and toxicity of local ablative therapy, with or without chemotherapy, for NSCLC patients with postoperative oligometastases at two centers.

**Patients and methods**

**Patients**

This study was approved by the ethics committee of Shandong Tumor Hospital, Affiliated to Shandong University and Tai’an Central Hospital. The ethics committee waived the requirement to obtain patient consent because of the retrospective study design. Between January 2005 and January 2016, patients with surgically resected NSCLC and oligometastases who accepted local ablative therapy, with or without chemotherapy, as the first-line treatment was enrolled in this study.

Postoperative pathological stage was based on the seventh edition of the American Joint Committee on Cancer. Chest/abdominal computed tomography (CT) scans, brain CT, magnetic resonance imaging (MRI), bone scintigraphy, or positron emission tomography (PET)/PET-CT scans were used to confirm the number of oligometastases, which was defined as \(\leq5\); mediastinal and supraclavicular lymph nodes in the same radiotherapy field were considered as an lesion. Patients with local recurrence in the surgical margin and ipsilateral hemithorax were excluded. Pathological confirmation was needed if a second primary tumor was suspected. All patients had metachronous metastases, indicating a disease-free interval (DFI) of \(\geq6\) months. Other criteria were age \(\geq18\) years, an Eastern Cooperative Oncology Group (ECOG) performance status score \(\leq2\), complete blood count and blood biochemistry within the normal range, and expected survival \(\geq3\) months. Patients, who harbored \(EGFR\) mutations, or \(ALK\) or \(ROS1\) rearrangements, were also excluded. Of the 221 patients with postoperative oligometastases, 163 were finally included for further study (Figure 1).

**Treatment regimens**

All patients were treated with local ablative therapy. The type of aggressive local therapy was determined by multidisciplinary teams. Patients who underwent surgery were required to have achieved radical (R0) resection. The targeted area of radiotherapy was required to include all metastases. Treatment doses were individualized based on tumor locations and organs at risk. Radiofrequency ablation, particle implantation, and embolization were performed according to the corresponding clinical guidelines. Chemotherapy was delivered either sequentially or concurrently.

**Outcome measures**

Local tumor response was assessed according to the Response Evaluation Criteria for Solid Tumors (RECIST) version 1.1 and confirmed by imaging. PFS refers to the time from the start of treatment to the first disease progression or death from any cause; OS refers to the time from the treatment date to the last follow-up or to any cause of death; and DFI was defined as the time from surgery to the occurrence of oligometastases. Acute toxicity data were collected using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

**Statistics**

SPSS 22.0 was used for statistical analyses. Student’s \(t\)-test was used to analyze continuous variables. Categorical variables were analyzed using the chi-squared test or Fisher’s exact test. Univariate and multivariate analyses of PFS and OS were evaluated using the Cox proportional hazards
regression model. Survival curves were constructed by the Kaplan–Meier method. \( P < 0.05 \) was considered to be statistically significant. All tests were two-sided.

**Results**

**Patients’ characteristics**

A total of 163 eligible patients were available for analysis in this study; of whom, 105 received local ablative therapy plus chemotherapy, whereas 58 underwent local ablative therapy alone. The baseline characteristics of all patients are presented in Table 1; no significant differences were detected between the two groups. Among patients with non-squamous carcinoma, adenocarcinoma was the predominant histological subtype, accounting for 80.6%. In the combination therapy group, 100 (95%) patients were treated with platinum-based doublet chemotherapy regimens, including 28 (26.7%), 34 (32.3%), 36 (34.2%), and two (1.9%) patients who received platinum combined with pemetrexed, gemcitabine, docetaxel, and etoposide, respectively. In addition, five (4.7%) patients were administered single-agent regimens with local ablative therapy.

**Survival and prognostic analyses**

For the entire cohort, the median OS after diagnosis of postoperative oligometastases was 19 months. The median OS for the combination therapy and local treatment groups was 19 (range, 1.5–107) months and 18.5 (range, 2–107) months, respectively (\( P = 0.498 \); Figure 2A). The 1-, 3-, and 5-year OS rates for the combination therapy group were 69.5%, 19.0%, and 6.7%, respectively; for the local treatment group, they were 65.5%, 20.7%, and 3.4%, respectively (\( P = 0.599, 0.801 \), and 0.493, respectively). The median PFS was 10 (range, 0–77) months in the combination therapy group and 7 (range, 0–70) months in the local treatment group, respectively (\( P = 0.006 \); Figure 2B). The 1- and 2-year PFS rates were 40.9% vs 25.9% (\( P = 0.054 \)) and 12.4% vs 8.6% (\( P = 0.463 \)) for the combination therapy and local treatment groups, respectively.

In univariate analyses, age at diagnosis (\( P < 0.001 \)) and tumor histology (\( P = 0.044 \)) were associated with OS (Table 2). In multivariate analyses, age was the only independent prognostic factor for OS (\( P < 0.001, HR 3.91, 95\% CI 1.83–8.38 \)). Notably, local ablative treatment with or without chemotherapy was not associated with OS. Both univariate and multivariate analyses identified DFI after surgery of \( \leq 24 \) months (\( P = 0.017 \) and 0.012, respectively) and treatment with local ablative treatment alone (\( P = 0.006 \) and 0.004, respectively) as significant unfavorable prognostic factors for PFS (Table 3).
Table 1 Characteristics of patients

| Characteristics                  | Local ablative therapy + chemotherapy (n=105) | Local ablative therapy alone (n=58) | P-value |
|----------------------------------|-----------------------------------------------|-----------------------------------|---------|
| Age (years), n (%)               |                                               |                                   |         |
| ≤65                              | 91 (86.7)                                     | 47 (81.0)                         | 0.339   |
| >65                              | 14 (13.3)                                     | 11 (19.0)                         |         |
| Gender, n (%)                    |                                               |                                   |         |
| Male                             | 82 (78.1)                                     | 46 (79.3)                         | 0.856   |
| Female                           | 23 (21.9)                                     | 12 (20.7)                         |         |
| Histology, n (%)                 |                                               |                                   |         |
| Squamous                         | 39 (37.1)                                     | 26 (44.8)                         | 0.337   |
| Non-squamous                     | 66 (62.9)                                     | 32 (55.2)                         |         |
| Differentiation, n (%)           |                                               |                                   |         |
| Low                              | 49 (46.7)                                     | 28 (48.3)                         | 1.000   |
| Intermediate/high                | 50 (47.6)                                     | 27 (46.5)                         |         |
| Unknown                          | 6 (5.7)                                       | 3 (5.2)                           |         |
| pTNM stage, n (%)                |                                               |                                   |         |
| I/II                             | 60 (57.2)                                     | 35 (60.3)                         | 0.437   |
| III                              | 39 (37.1)                                     | 17 (29.3)                         |         |
| Unknown                          | 6 (5.7)                                       | 6 (10.4)                          |         |
| ECOG PS, n (%)                   |                                               |                                   |         |
| 0                                | 36 (34.3)                                     | 17 (29.3)                         | 0.529   |
| 1                                | 58 (55.2)                                     | 37 (63.8)                         |         |
| 2                                | 11 (10.5)                                     | 4 (6.9)                           |         |
| Adjuvant therapy, n (%)          |                                               |                                   |         |
| Chemotherapy                     | 80 (76.2)                                     | 42 (72.4)                         | 0.820   |
| Chemoradiotherapy                | 9 (8.6)                                       | 5 (8.6)                           |         |
| Others                           | 16 (15.2)                                     | 11 (19.0)                         |         |
| Disease-free interval (months), n (%) |                                   |                                   |         |
| ≤24                              | 73 (69.5)                                     | 37 (63.8)                         | 0.455   |
| >24                              | 32 (30.5)                                     | 21 (36.2)                         |         |
| Image diagnosis, n (%)           |                                               |                                   |         |
| PET                              | 16 (15.2)                                     | 10 (17.2)                         | 0.738   |
| CT/MRI/ECT                       | 89 (84.8)                                     | 48 (82.8)                         |         |
| Metastasis, n (%)                |                                               |                                   |         |
| 1                                | 77 (73.3)                                     | 48 (82.8)                         | 0.173   |
| 2–5                              | 28 (26.7)                                     | 10 (17.2)                         |         |
| Local ablative therapy, n (%)    |                                               |                                   |         |
| Radiotherapy                     | 93 (88.6)                                     | 49 (84.5)                         | 0.072   |
| Surgery                          | 10 (9.5)                                      | 3 (5.2)                           |         |
| Radiotherapy + surgery           | 0 (0.0)                                       | 1 (1.7)                           |         |
| Othersa                          | 2 (1.9)                                       | 5 (8.6)                           |         |
| Metastasis location, n (%)       |                                               |                                   |         |
| Regional lymph nodes             | 48 (45.7)                                     | 22 (37.9)                         | 0.124   |
| Brain                            | 25 (23.8)                                     | 21 (36.2)                         |         |
| Lung                             | 20 (19.0)                                     | 7 (12.1)                          |         |
| Bone                             | 18 (17.1)                                     | 4 (6.9)                           |         |
| Adrenal gland                    | 5 (4.8)                                       | 1 (1.7)                           |         |
| Liver                            | 1 (1.0)                                       | 3 (5.2)                           |         |
| Othersa                          | 8 (7.6)                                       | 5 (8.6)                           |         |

Notes: In addition to radiotherapy and surgery, one patient underwent radiofrequency ablation and one underwent particle implantation in the combination therapy group, whereas four underwent embolizations and one received particle implantation in the local treatment group. aOther metastasis sites included the chest wall and retroperitoneal lymph nodes.

Abbreviations: CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance score; ECT, emission computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; pTNM, Pathological Tumor-Node-Metastasis.
Table 2 Univariate and multivariate analyses of overall survival

| Variables                          | Patients (n=163) | Univariate analysis | Multivariate analysis |
|------------------------------------|------------------|---------------------|-----------------------|
|                                    |                  | P-value | HR (95% CI) | P-value | HR (95% CI) |
| Age (years)                        |                  |         |             |         |             |
| ≤65                                | 138              | <0.001  | 3.91 (1.83–8.38) | <0.001  | 3.91 (1.83–8.38) |
| >65                                | 25               | I       |             | I       |             |
| Gender                             |                  | 0.893   | I           |         |             |
| Male                               | 128              |         |             |         |             |
| Female                             | 35               | 0.94 (0.39–2.30) |         |         |             |
| Histology                          |                  | 0.044   | I           |         |             |
| Squamous                           | 65               |         |             |         |             |
| Non-squamous                       | 98               | 0.49 (0.25–0.98) |         |         |             |
| Differentiation                    |                  | 0.833   | I           |         |             |
| Low                                | 77               |         |             |         |             |
| Intermediate/high                  | 77               | 0.90 (0.43–1.88) |         |         |             |
| Unknown                            | 9                | 0.64 (0.15–2.83) |         |         |             |
| pTNM stage                         |                  | 0.115   | I           |         |             |
| I/II                               | 95               |         |             |         |             |
| III                                | 56               | 1.62 (0.78–3.35) |         |         |             |
| Unknown                            | 12               | 0.23 (0.03–1.76) |         |         |             |
| Disease-free interval (months)     |                  | 0.332   | I           |         |             |
| ≤24                                | 110              |         |             |         |             |
| >24                                | 53               | 0.69 (0.32–1.47) |         |         |             |
| Metastasis                         |                  | 0.340   | I           |         |             |
| 1                                  | 125              |         |             |         |             |
| 2–5                                | 38               | 1.44 (0.68–3.07) |         |         |             |
| ECOG PS                            |                  | 0.684   | I           |         |             |
| 0                                  | 53               |         |             |         |             |
| 1                                  | 95               | 0.84 (0.40–1.77) |         |         |             |
| 2                                  | 15               | 1.34 (0.43–4.20) |         |         |             |
| Metastasis location                |                  | 0.657   | I           |         |             |
| Extracranial                       | 116              |         |             |         |             |
| Intracranial                       | 47               | 1.20 (0.53–2.70) |         |         |             |
| Treatment                          |                  |         |             |         |             |
| Local ablative therapy + chemotherapy | 105              | 0.498   | I           |         |             |
| Local ablative therapy alone       | 58               | 1.28 (0.63–2.58) |         |         |             |

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance score; pTNM, Pathological Tumor-Node-Metastasis.

Figure 2 Kaplan–Meier curves of OS (A) and PFS (B) for the local ablative therapy with or without chemotherapy in NSCLC patients with postoperative oligometastases. Abbreviations: NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival.
Among the 105 patients in the combination therapy group, 13 complete responses (12.4%), 57 partial responses (54.3%), 29 disease stabilizations (27.6%), and six progressions (5.7%) were recorded, resulting in an objective response rate (ORR) of 66.7%, whereas the ORR for the group receiving local ablative therapy alone was 46.5% ($P=0.012$; Table 4).

The failure patterns after treatment of postoperative oligometastases were also further analyzed, and no significant difference between the two groups was detected in local failure, distant failure, or combination failure ($P=0.218$, 0.149, and 0.991, respectively; Table 4).

**Toxicities**

Treatment-related acute toxicities are listed in Table 5. The most common adverse events in both groups were myelosuppression, nausea/vomiting, fatigue, and radiation esophagitis. The incidences of grade $\geq 3$ myelosuppression and nausea/vomiting were markedly higher in the combination therapy group than in the local treatment group (24.8% and 3.5%, respectively, $P=0.001$). In addition, in the combination therapy group, one patient developed grade 3 esophagitis and an elderly patient (aged 72 years) died of fungal pneumonia.

**Discussion**

We reported a two-institution retrospective study comparing the efficacy and toxicity of local ablative treatment plus chemotherapy vs local treatment alone in NSCLC patients with postoperative oligometastases. The group who received local treatment combined with chemotherapy had superior PFS and ORR (10 vs 7 months, $P=0.006$; 66.7% vs 46.5%, $P=0.012$); however, there was no significant difference in

---

**Table 3** Univariate and multivariate analyses of progression-free survival

| Variables                           | Patients (n=163) | Univariate analysis | Multivariate analysis |
|-------------------------------------|------------------|---------------------|-----------------------|
|                                     |                  | P-value | HR (95% CI)   | P-value | HR (95% CI)   |
| Age (years)                         |                  |         |               |         |               |
| $\leq$65                            | 138              | 0.818   | 1             |         |               |
| $>65                                | 25               | 0.94 (0.53–1.64) | 1         |               |
| Gender                              |                  |         |               |         |               |
| Male                                | 128              | 0.899   | 1             |         |               |
| Female                              | 35               | 1.03 (0.65–1.64) | 1         |               |
| Histology                           |                  |         |               |         |               |
| Squamous                            | 65               | 0.545   | 1             |         |               |
| Non-squamous                        | 98               | 1.13 (0.77–1.65) | 1         |               |
| Differentiation                     |                  |         |               |         |               |
| Low                                 | 77               | 0.592   | 1             |         |               |
| Intermediate/high                   | 77               | 0.81 (0.38–1.72) | 1         |               |
| Unknown                             | 9                | 0.98 (0.47–2.07) | 1         |               |
| pTNM stage                          |                  |         |               |         |               |
| I/II                                | 95               | 0.088   | 1             |         |               |
| III                                 | 56               | 1.40 (0.94–2.08) | 1         |               |
| Unknown                             | 12               | 0.70 (0.36–1.36) | 1         |               |
| Disease-free interval (months)      |                  |         |               |         |               |
| $\leq$24                            | 110              | 0.017   | 1             | 0.012   | 1             |
| $>24                                | 53               | 0.61 (0.41–0.92) | 1         | 0.60 (0.40–0.89) |
| Metastasis                          |                  |         |               |         |               |
| 1                                   | 125              | 0.185   | 1             |         |               |
| 2–5                                 | 38               | 1.32 (0.88–2.00) | 1         |               |
| ECOG PS                             |                  |         |               |         |               |
| 0                                   | 53               | 0.669   | 1             |         |               |
| 1                                   | 95               | 0.97 (0.65–1.46) | 1         |               |
| 2                                   | 15               | 1.32 (0.65–2.67) | 1         |               |
| Metastasis location                 |                  |         |               |         |               |
| Extracranial                        | 116              | 0.071   | 1             |         |               |
| Intracranial                        | 47               | 1.44 (0.97–2.15) | 1         |               |
| Treatment                           |                  |         |               |         |               |
| Local ablative therapy + chemotherapy| 105             | 0.006   | 1             | 0.004   | 1             |
| Local ablative therapy alone        | 58               | 1.68 (1.16–2.44) | 1         | 1.73 (1.19–2.51) |

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance score; pTNM, Pathological Tumor-Node-Metastasis.
OS between the two groups (19 vs 18.5 months, \(P=0.498\)), whereas the incidence of grade \(\geq 3\) toxicities was markedly higher in the combination group.

The optimal treatment strategy for NSCLC patients with postoperative oligometastases remains controversial. Emerging evidence indicates that local treatment of postoperative oligometastases predicts a favorable PRS and even cure;\(^{19}\) however, most studies emphasizing the role of local therapy enrolled patients receiving local therapy alone and those receiving local therapy plus systemic treatment, simultaneously,\(^{16,20}\) which complicates evaluation of the value of adding chemotherapy to local therapy. To the best of our knowledge, this is the first study to compare the effects of local ablative treatment plus chemotherapy vs local treatment alone in NSCLC patients with postoperative oligometastases.

Although PFS and ORR were superior in patients receiving combination therapy, these did not translate into improved OS. Failure patterns following treatment of postoperative oligometastases also did not differ between the two groups. Considering the finding that oligometastases have not acquired the broad array of genetic changes associated with development of widespread metastases,\(^{21}\) it is unclear whether they are biologically indolent, irrespective of the chemotherapy provided. Further study is needed to compare the efficacy of local therapy vs chemotherapy.

Analysis of prognostic factors for patients with postoperative oligometastatic NSCLC demonstrated that age and DFI could independently predict OS and PFS, respectively, consistent with previous studies.\(^{22-24}\) As younger patients can better tolerate the intensive therapy following failure of first-line treatment, it is not surprising that age \(\leq 65\) years may be a marker of superior survival in patients with recurrent NSCLC. DFI, a variable directly describing tumor biology, is an independent factor predicting patient prognosis after recurrent NSCLC. Longer DFI, suggesting relatively slow tumor growth,\(^{25}\) was favorably associated with long-term survival (\(\geq 5\) years).\(^{23}\) Thus, these factors may be considered when estimating patient prognosis and could be helpful for providing individualized treatment for NSCLC patients with postoperative oligometastases.

Given their prolonged PFS and superior ORR, selected NSCLC patients with postoperative oligometastases would benefit from combination therapy with local ablative treatment plus chemotherapy. MicroRNA markers, which have been determined to successfully distinguish patients with oligometastases-directed SBRT,\(^{26}\) will be useful for
identifying subsets of patients who would receive both PFS and OS benefits from local ablative treatment plus chemotherapy. Further development of other markers, such as circulating tumor DNA and circulating tumor cells, is also awaited.

This study enrolled patients without EGFR, ALK, or ROS1 mutations, who may not benefit from treatment with tyrosine kinase inhibitors (TKIs). In the new era of targeted therapy, immunotherapy may be an alternative choice for NSCLC patients with postoperative oligometastases. Immunotherapy is a promising therapeutic option for the management of metastatic NSCLC. Combining immunotherapy with radiotherapy was found to further improve both local and distant diseases through enhanced T-cell activation.

Nevertheless, many patients did not respond to this type of combination therapy. Further understanding of the biological characteristics of postoperative oligometastases will be valuable for individualized treatment of patients with NSCLC and appropriate selection of patients who would benefit from local radiotherapy alone, local radiotherapy plus immunotherapy, or local radiotherapy plus chemotherapy, which may ultimately expand the survival benefit to more patients.

Like other retrospective studies, this study has some limitations. Bias was unavoidable, since the choice of treatment may be influenced by the physicians’ preferences and experiences. Although patients with oligometastases were identified by analyses of all available imaging findings, PET-CT was not commonly performed at the time of recurrence.

Conclusion
This study is the first to indicate that local therapy combined with chemotherapy improved PFS and ORR for NSCLC patients with postoperative oligometastases, but failed to prolong OS. Considering the increased incidence of grade ≥3 toxicities, this type of combination treatment should be used with caution and limited to specific patients. A prospective and randomized trial of local ablative treatment plus chemotherapy vs local treatment alone is urgently needed to validate these findings.

Abbreviations
ALK, anaplastic lymphoma kinase; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; DFI, disease-free interval; ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PET, positron emission tomography; PFS, progression-free survival; PRS, post recurrence survival; RECIST, Response Evaluation Criteria for Solid Tumors; ROS1, c-ros oncogene 1 kinase; SBRT, stereotactic body radiation therapy; TKIs, tyrosine kinase inhibitors.

Ethics approval and informed consent
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the Declaration of Helsinki (1964) and its later amendments or comparable ethical standards. For this retrospective study, the ethics committee waived the requirement to obtain patient consent, but all data were kept confidential.

Acknowledgment
This work was supported by the Project of Postdoctoral Science Foundation of China (Grant No: 2016M590640), the Project of Postdoctoral Innovation of Shandong Province (Grant No: 201501010), National Health and Family Planning Commission of China (201402011), and National Natural Science Foundation of China (81472812).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115(22):5218–5227.
2. al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997;12(3):380–384.
3. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109(1):120–129.
4. Martin J, Ginsberg RJ, Venkatraman ES, et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 2002;20(8):1989–1995.
5. Dziedzic DA, Rudzinski P, Langfort R, Orłowski T; Polish Lung Cancer Study Group (PLCSG). Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer. Clin Lung Cancer. 2016;17(5):e157–e167.
6. Pflannschmidt J. Editorial on “Long-term survival outcome after postoperative recurrence of non-small cell lung cancer: who is ‘cured’ from postoperative recurrence?” J Thorac Dis. 2018;10(2):610–613.
7. Torok JA, Gu L, Tandberg DJ, et al. Patterns of distant metastases after surgical management of non-small-cell lung cancer. Clin Lung Cancer. 2017;18(1):e57–e70.
8. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.
9. Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682.
10. Nakamura M, Hashimoto N, Mayahara H, et al. Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence. *Radiat Oncol.* 2018;13(1):75.

11. Bae SH, Ahn YC, Nam H, et al. High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. *Yonsei Med J.* 2012;53(6):1120–1127.

12. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. *J Thorac Oncol.* 2009;4(4):518–521.

13. Shimada Y, Saji H, Kakehana M, Kajiwara N, Ohira T, Ikeda N. Survival outcomes for oligometastasis in resected non-small cell lung cancer. *Asian Cardiovasc Thorac Ann.* 2015;23(8):937–944.

14. Niibe Y, Nishimura T, Inoue T, et al. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects. *BMC Cancer.* 2016;16(1):659.

15. De Wolf J, Bellier J, Lepimpec-Barthes F, et al. Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study. *Eur J Cardiothorac Surg.* 2017;52(4):698–703.

16. Yamashita H, Niibe Y, Yamamoto T, et al. Lung stereotactic radiotherapy for oligometastases: comparison of oligo-recurrence and sync-oligo-metastases. *Jpn J Clin Oncol.* 2016;46(7):687–691.

17. Hishida T, Yoshida J, Aokage K, Nagai K, Tsuboi M. Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival. *Eur J Cardiothorac Surg.* 2016;49(3):847–853.

18. Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. *Cancer J.* 2006;12(4):283–288.

19. Sekihara K, Hishida T, Yoshida J, et al. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence? *Eur J Cardiothorac Surg.* 2017;52(3):522–528.

20. Yano T, Okamoto T, Haro A, et al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. *Long Cancer.* 2013;82(3):431–435.

21. Weichselbaum RR, Hellman S. Oligometastases revisited. *Nat Rev Clin Oncol.* 2011;8(6):378–382.

22. Yano T, Haro A, Yoshida T, et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer. *J Surg Oncol.* 2010;102(7):852–855.

23. Howell GM, Carty SE, Armstrong MJ, et al. Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. *Ann Surg Oncol.* 2013;20(11):3491–3496.

24. Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. *Clin Lung Cancer.* 2014;15(5):346–355.

25. Walsh GL, O’Connor M, Willis KM, et al. Is follow-up of lung cancer patients after resection medically indicated and cost-effective? *Ann Thorac Surg.* 1995;60(6):1563–1570.

26. Wong AC, Watson SP, Pitroda SP, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). *Cancer.* 2016;122(14):2242–2250.

27. Ignatiadis M, Lee M, Jeffrey SS. Circulating tumor cells and circulating tumor DNA: Challenges and opportunities on the path to clinical utility. *Clin Cancer Res.* 2015;21(21):4786–4800.

28. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med.* 2015;372(21):2018–2028.

29. Brahmer J, Reckamp KL, Baas P, et al; Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med.* 2015;373(2):123–135.

30. Bristow RG, Alexander B, Baumann M, et al. Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. *Lancet Oncol.* 2010;11(5):e240–e251.